Cell therapy products is >$1 billion market with aggressive annual growth rates (15- 20%). Of all of the cells therapies currently in development, mesenchymal stem cells (MSCs) appear to have the greatest diversity of applications and potential for widespread use. Mesenchymal stem/stromal cells (MSCs) are being investigated for a variety of applications. Currently, over 200 clinical trials involve the use of MSCs and over 2000 patients have been safely treated with MSCs. MSCs are being investigated for treatment of cardiovascular disorders (stroke, myocardial infarction), diabetes, connective tissue disorders (cartilage defects, osteonecrosis, limb ischemia), chronic obstructive pulmonary disease, nervous system disorders (multiple sclerosis, Parkinson Disease, spinal cord injury), kidney diseases and more. Current methods for the preservation of MSCs are suboptimal. Improper methods of preservation are felt to have contributed to a recent failure of a Phase III clinical tral. In addition, the infusion of DMSO-containing cells is associated with adverse events that have been well documented in the clinical literature. Clinical and commercial application of MSCs will require the development of protocols that produce a consistent number of viable and functional cells. The proposed investigation transforms not only the preservation protocol for MSCs but creates a new paradigm by which preservation protocols for other cell types can be developed. We propose to use synergy between multiple preservation compounds to improve preservation outcome and replace conventional toxic cryoprotective agents such as DMSO. Testing solutions using multiple compounds would normally require thousands of experiments. We accelerate the convergence of the studies using a computational algorithm. Finally, we will use molecular dynamics to understand molecular mechanisms of action and rationally select compounds appropriate for testing. This type of approach will be applied first of all to MSCs but can be extended to a variety of different cell types used therapeutically. !
Mesenchymal stem cells are being used to treat a variety of diseases but clinical use of the cells has been limited by the quality of cells post thaw. We are proposing to develop an optimal protocol for the preservation of MSCs using stabilizing agents safe not only for the cells and patients receiving the cells. A more effective protocol for preserving MSCs will enable the treatment of more diseases using these cells and more people being able to receive cell-based therapies.
|Yu, Guanglin; Yap, Yan Rou; Pollock, Kathryn et al. (2017) Characterizing Intracellular Ice Formation of Lymphoblasts Using Low-Temperature Raman Spectroscopy. Biophys J 112:2653-2663|
|Pollock, Kathryn; Budenske, Joseph W; McKenna, David H et al. (2017) Algorithm-driven optimization of cryopreservation protocols for transfusion model cell types including Jurkat cells and mesenchymal stem cells. J Tissue Eng Regen Med 11:2806-2815|
|Pollock, Kathryn; Samsonraj, Rebekah M; Dudakovic, Amel et al. (2017) Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions. Stem Cells Dev 26:828-842|
|Pollock, Kathryn; Yu, Guanglin; Moller-Trane, Ralph et al. (2016) Combinations of Osmolytes, Including Monosaccharides, Disaccharides, and Sugar Alcohols Act in Concert During Cryopreservation to Improve Mesenchymal Stromal Cell Survival. Tissue Eng Part C Methods 22:999-1008|
|Pollock, Kathryn; Sumstad, Darin; Kadidlo, Diane et al. (2015) Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. Cytotherapy 17:38-45|
|Sharma, Ratti Ram; Pollock, Kathryn; Hubel, Allison et al. (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54:1418-37|